Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILD
HealthcareNASDAQUnited States
137.13USD-0.21 (-0.15%)

About Gilead

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for areas of unmet medical need in the United States, Europe, and internationally.

The company focuses on:

  • HIV/AIDS: Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Atripla (HIV treatment and prevention)

  • Liver Diseases: Epclusa, Harvoni, Vosevi (hepatitis C), Vemlidy, Viread (hepatitis B)

  • COVID-19: Veklury (remdesivir, intravenous antiviral for COVID-19)

  • Oncology & Cell Therapy: Yescarta, Tecartus (CAR T-cell therapies), Trodelvy (triple-negative breast cancer and urothelial cancer), Zydelig (chronic lymphocytic leukemia and follicular lymphoma)

  • Pulmonary & Cardiovascular: Letairis (pulmonary arterial hypertension), Ranexa (chronic angina)

  • Anti-infectives: AmBisome (serious invasive fungal infections)

Collaborations: Gilead has partnership agreements with Arcus Biosciences, Pionyr Immunotherapeutics, Tizona Therapeutics, Tango Therapeutics, Jounce Therapeutics, Galapagos NV, Janssen Sciences, Japan Tobacco, Gadeta B.V., Bristol-Myers Squibb, Dragonfly Therapeutics, and Merck & Co.

Gilead Sciences was incorporated in 1987 and is headquartered in Foster City, California.

Gilead's Business Strategy

Gilead operates with a dual-focus strategy balancing its established leadership in viral diseases (HIV, hepatitis) with a strategic expansion into oncology and inflammatory conditions. The company's business model has evolved from historically developing small molecule antivirals to a broader approach incorporating biologics and cell therapies.

Revenue…

Available on Finplify

Free account required

Sign up free

Our Take on Gilead

Pros:

HIV & Antiviral Therapies Strong Franchise: Gilead is a global leader in HIV treatment, with a highly resilient and recurring revenue stream from its best-in-class therapies like Biktarvy and Descovy. The company’s antiviral expertise also extends to hepatitis C and COVID-related antivirals.

✅ **HIV…

Available on Finplify

Free account required

Sign up free

Company Details

Exchange
NASDAQ
Country
United States
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Daniel O'Day
Employees
17,600
IPO Date
1992-01-22
ISIN
US3755581036
Website
gilead.com

Key Metrics

Market Cap
170.24BUSD
P/E Ratio (TTM)
20.04
Net Profit Margin
28.90%
Debt / Asset Ratio
0.42
Dividend Yield (TTM)
2.32%
Volume
877,132
Avg Volume
7.38M
Shares Outstanding
1.24B
Free Float
99.79%
β Beta
0.39
52W Range
93.4 - 157.3

Fundamental Analysis

Proprietary 5-category scoring system

Score Fingerprint

Section Scores

Profitability
4.8/5Excellent
Liquidity
4.0/5Good
Leverage
3.0/5Average
Cash Flow
4.0/5Good
Valuation
3.9/5Good

Full Breakdown & Peer Ranking

See the detailed score for every metric and how this stock ranks against its sector peers

Unlock for free
Free to join

Unlock the full research on Gilead

Get the full fundamental score breakdown, business strategy, our investment take, live charts and AI-powered briefings. All in one ad-free workspace.

300+ Curated Stocks

A hand-picked universe of world-class businesses across every major market and sector.

AI Analyst Briefings

Deploy your own AI analyst that monitors your portfolio and delivers daily intelligence reports.

Proprietary Fundamentals

Five-category scoring for every stock — profitability, liquidity, leverage, cash flow, and valuation.